1. Pfizer's acquisition of Seagen enhances its ADC technology, potentially expanding its oncology franchise and driving future growth; 2. PFE's development of the oral GLP-1 receptor agonist, Danuglipron, aims to capture the growing obesity and diabetes treatment market by 2028; 3. The Company anticipates 11.4% revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization, despite challenges from declining COVID-related revenue.